Connections between prolactin and ovarian cancer.

Carcinoma, Ovarian Epithelial / metabolism Cell Movement / drug effects Cell Proliferation / drug effects Female Humans Immunohistochemistry Kaplan-Meier Estimate MCF-7 Cells Ovarian Neoplasms / metabolism Phosphorylation / drug effects Progression-Free Survival Prolactin / pharmacology RNA, Messenger / genetics Real-Time Polymerase Chain Reaction Receptors, Prolactin / genetics Recombinant Proteins / pharmacology STAT3 Transcription Factor / metabolism STAT5 Transcription Factor / metabolism Signal Transduction / drug effects Survival Rate

Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 18 04 2021
accepted: 22 07 2021
entrez: 6 8 2021
pubmed: 7 8 2021
medline: 15 12 2021
Statut: epublish

Résumé

Ovarian cancer (OC) is characterized by a high morbidity and mortality, highlighting a great need for a better understanding of biological mechanisms that affect OC progression and improving its early detection methods. This study investigates effects of prolactin (PRL) on ovarian cancer cells, analyzes PRL receptors (PRLR) in tissue micro arrays and relates PRLR expression to survival of ovarian cancer. A database, composed of transcript profiles from OC, was searched for PRLR expression and results were put in relation to survival. Expression of PRLR in OC tissue sections and OC cell lines SKOV3, OV2008 and OVSAHO was assessed using immunohistochemistry, western blots and quantitative real-time PCR. The biological function of PRLR was evaluated by proliferation, colony formation and wound healing assays. Levels of PRLR mRNA are related to survival; in epithelial OC a high PRLR mRNA expression is related to a shorter survival. Analysis of a tissue micro array consisting of 84 OC showed that 72% were positive for PRLR immuno-staining. PRLR staining tended to be higher in OC of high grade tumors compared to lower grades. PRLR mRNA and protein can further be detected in OC cell lines. Moreover, in vitro treatment with PRL significantly activated the JAK/STAT pathway. PRLR expression is associated with OC survivals. PRL and its receptor may play an onco-modulatory role and promote tumor aggressiveness in OC. Alternatively, increased PRLR levels may form a base for the development of PRLR antagonist or PRLR antagonist-drug conjugate to increase selective uptake of anti-cancer drugs.

Identifiants

DOI: 10.1371/journal.pone.0255701 PMID: 34358244 PMC: PMC8345882
pubmed: 34358244
doi: 10.1371/journal.pone.0255701
pii: PONE-D-21-12812
pmc: PMC8345882
doi:

Substances chimiques

RNA, Messenger 0
Receptors, Prolactin 0
Recombinant Proteins 0
STAT3 Transcription Factor 0
STAT3 protein, human 0
STAT5 Transcription Factor 0
Prolactin 9002-62-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0255701

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82
pubmed: 15890779
J Obstet Gynaecol Res. 2009 Oct;35(5):918-25
pubmed: 20149042
Cancer Causes Control. 2013 Apr;24(4):741-8
pubmed: 23378139
Indian J Cancer. 2014 Mar;51 Suppl 3:e72-6
pubmed: 25818738
Evid Rep Technol Assess (Full Rep). 2006 Feb;(130):1-145
pubmed: 17854238
Endocrinology. 2013 Dec;154(12):4777-89
pubmed: 24029242
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
Gynecol Oncol. 2004 Sep;94(3):630-5
pubmed: 15350351
Semin Reprod Endocrinol. 1999;17(1):23-7
pubmed: 10406072
J Gynecol Oncol. 2014 Jul;25(3):174-82
pubmed: 25045429
Biology (Basel). 2020 Feb 27;9(3):
pubmed: 32121009
Endocr Rev. 1995 Jun;16(3):354-69
pubmed: 7671851
Mod Pathol. 2009 Oct;22(10):1273-9
pubmed: 19633648
Mol Endocrinol. 1994 Mar;8(3):356-73
pubmed: 8015553
Mol Endocrinol. 1994 May;8(5):635-42
pubmed: 8058071
Pathology. 2011 Aug;43(5):420-32
pubmed: 21716157
Eur J Cancer Clin Oncol. 1988 Dec;24(12):1851-3
pubmed: 3065085
J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):147-56
pubmed: 18246318
Obstet Gynecol. 2012 Sep;120(3):612-8
pubmed: 22914471
PLoS One. 2019 May 7;14(5):e0215831
pubmed: 31063493
J Mammary Gland Biol Neoplasia. 1997 Jan;2(1):7-17
pubmed: 10887515
Trends Endocrinol Metab. 2002 Aug;13(6):245-50
pubmed: 12128285
Cancers (Basel). 2019 Dec 19;12(1):
pubmed: 31861720
Mol Cell Proteomics. 2004 Apr;3(4):355-66
pubmed: 14764655
Oncologist. 2016 May;21(5):535-6
pubmed: 27091421
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):802-7
pubmed: 15647370
Nat Genet. 2012 Jun 24;44(8):941-5
pubmed: 22729223
Endocr Rev. 1996 Dec;17(6):639-69
pubmed: 8969972
J Clin Invest. 1997 Feb 15;99(4):618-27
pubmed: 9045863
Annu Rev Physiol. 2002;64:47-67
pubmed: 11826263
Endocr Rev. 2005 May;26(3):400-22
pubmed: 15814850
Science. 2004 Aug 20;305(5687):1163-7
pubmed: 15284455
J Mol Endocrinol. 2016 Nov;57(4):R153-R165
pubmed: 27658959
Physiol Rev. 2000 Oct;80(4):1523-631
pubmed: 11015620
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Front Genet. 2018 Nov 19;9:555
pubmed: 30510566
Nat Rev Urol. 2011 Oct 04;8(11):597-607
pubmed: 21971318
Oncol Lett. 2013 Sep;6(3):789-794
pubmed: 24137412
Oncogene. 2017 Jan 12;36(2):168-181
pubmed: 27292260
Gynecol Oncol. 2016 Mar;140(3):474-80
pubmed: 26743531
Front Immunol. 2017 Jun 23;8:720
pubmed: 28690611
Int Immunol. 2008 Mar;20(3):327-36
pubmed: 18187558
Cancer Res. 2009 Jun 15;69(12):5226-33
pubmed: 19491263
Gynecol Oncol. 2006 Jan;100(1):20-6
pubmed: 16188302
Mol Cancer Ther. 2017 Jul;16(7):1299-1311
pubmed: 28377489
Oncotarget. 2016 Nov 29;7(48):79572-79583
pubmed: 27788487
Eur Urol. 2003 Mar;43(3):301-8
pubmed: 12600435
PLoS One. 2016 Jan 14;11(1):e0146653
pubmed: 26765535
J Inflamm (Lond). 2013 Jun 03;10(1):24
pubmed: 23731754
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
Oncotarget. 2016 May 17;7(20):29465-79
pubmed: 27102295
Br J Cancer. 2004 Jul 19;91(2):305-11
pubmed: 15213724
Gynecol Oncol. 2003 May;89(2):233-5
pubmed: 12713985
Breast Cancer Res Treat. 2011 Jul;128(1):31-40
pubmed: 20658264
Electron Physician. 2015 Oct 19;7(6):1399-406
pubmed: 26516450
Mol Cancer Res. 2018 Jul;16(7):1185-1195
pubmed: 29724813

Auteurs

Amira Alkharusi (A)

Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
ORCID: 0000-0002-6671-4431

Abdullah AlMuslahi (A)

Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

Najwa AlBalushi (N)

Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

Radiya AlAjmi (R)

Department of Pathology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

Sami AlRawahi (S)

Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

Asmaa AlFarqani (A)

Department of Physiology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

Gunnar Norstedt (G)

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Fahad Zadjali (F)

Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
ORCID: 0000-0001-5891-4700

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Carcinome épithélial de l'ovaire › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Phénomènes physiologiques › Mouvement cellulaire › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Immunohistochimie › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Estimation de Kaplan-Meier › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Cellules › Cellules cultivées › Lignée cellulaire › Cellules MCF-7 › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Maladies endocriniennes › Troubles gonadiques › Maladies ovariennes › Tumeurs de l'ovaire › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Métabolisme › Phosphorylation › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans progression › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Acides aminés, peptides et protéines › Peptides › Hormones peptidiques › Hormones hypophysaires › Hormones antéhypophysaires › Prolactine › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN messager › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Techniques d'investigation › Techniques génétiques › Techniques d'amplification d'acides nucléiques › Réaction de polymérisation en chaîne › Réaction de polymérisation en chaine en temps réel › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs peptidiques › Récepteur hormone hypophysaire › Récepteur gonadotrophine › Récepteur prolactine › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines recombinantes › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription STAT › Facteur de transcription STAT-3 › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Facteurs de transcription STAT › Facteur de transcription STAT-5 › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Connections between prolactin and ovarian cancer.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Mortalité › Taux de survie › Connections between prolactin and ovarian cancer.